Inozyme Pharma Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Inozyme pharma daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Inozyme Pharma Daily Today - Breaking & Trending Today

Inozyme Pharma (NASDAQ:INZY) Given Outperform Rating at Wedbush

Wedbush restated their outperform rating on shares of Inozyme Pharma (NASDAQ:INZY – Free Report) in a report issued on Monday, RTT News reports. Wedbush currently has a $15.00 price objective on the stock. Separately, HC Wainwright restated a buy rating and set a $16.00 target price on shares of Inozyme Pharma in a research note […] ....

Inozyme Pharma , Douglasa Treco , Schonfeld Strategic Advisors , Securities Exchange Commission , Inozyme Pharma Inc , Inozyme Pharma Company Profile , Eventide Asset Management , Free Report , Get Free Report , Exchange Commission , Capital Partners , Strategic Advisors , Capital Management , Asset Management , Inozyme Pharma Daily , Nasdaq Inzy , Reiterated Rating ,

Inozyme Pharma's (INZY) "Outperform" Rating Reaffirmed at Wedbush

Inozyme Pharma's (INZY) "Outperform" Rating Reaffirmed at Wedbush
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Douglasa Treco , Inozyme Pharma , Inozyme Pharma Inc , Securities Exchange Commission , Renaissance Technologies , Blackrock Inc , Citigroup Inc , Inozyme Pharma Company Profile , Get Free Report , Exchange Commission , Rock Springs Capital Management , Springs Capital Management , Inozyme Pharma Daily ,

Wedbush Reiterates Outperform Rating for Inozyme Pharma (NASDAQ:INZY)

Wedbush Reiterates Outperform Rating for Inozyme Pharma (NASDAQ:INZY)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United States , Inozyme Pharma , Douglasa Treco , Dimensional Fund Advisors , Charles Schwab Investment Management Inc , Inozyme Pharma Inc , Securities Exchange Commission , Inozyme Pharma Company Profile , America Corp , Barclays Plc , Tower Research Capital , Get Free Report , Exchange Commission , Fund Advisors , Research Capital , Charles Schwab Investment Management , Schwab Investment Management , Inozyme Pharma Daily ,

Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Sells $52,209.62 in Stock

Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) CEO Douglas A. Treco sold 7,523 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $6.94, for a total value of $52,209.62. Following the completion of the sale, the chief executive officer now owns 20,665 […] ....

Inozyme Pharma , Douglasa Treco , Inozyme Pharma Company Profile , Inozyme Pharma Inc , Securities Exchange Commission , Eventide Asset Management , Blackrock Inc , Blue Owl Capital Holdings , Get Free Report , Exchange Commission , Asset Management , Capital Partners , Inozyme Pharma Daily , Nasdaq Inzy , Insider Trading , Nsider Trades ,

Inozyme Pharma, Inc. (NASDAQ:INZY) CEO Douglas A. Treco Sells 7,523 Shares

Inozyme Pharma, Inc. (NASDAQ:INZY – Get Free Report) CEO Douglas A. Treco sold 7,523 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $6.94, for a total value of $52,209.62. Following the completion of the sale, the chief executive officer now […] ....

Douglasa Treco , Inozyme Pharma , Inozyme Pharma Inc , Inozyme Pharma Company Profile , Tower Research Capital , Renaissance Technologies , Get Free Report , Research Capital , Sigma Investments , Inozyme Pharma Daily , Nasdaq Inzy , Insider Trading , Nsider Trades ,